Korro Bio (KRRO) director-tied funds sell 28K shares on Aug. 19

H.C. Wainwright reiterated a Buy rating and $15.00 price target for Korro Bio (KRRO) after the company dosed the first cohort in its Phase 1/2 trial for KRRO-121. The stock is down 77% over the past year, trading at $9.97. Korro Bio has a strong current ratio of 9.55 and more cash than debt. The ANCHOR trial is expected to take about a year, with primary completion estimated for the second half of 2027.

Korro Bio, Inc. (KRRO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121 • Initiated a Phase 1/2 clinical trial to enroll healthy volunteers and patients with Urea Cycle Disorders of any mutational background • Administered a single dose of 2mg/kg to the

Korro Bio (KRRO) has dosed the first cohort in its Phase 1/2 trial for KRRO-121, an RNA-editing treatment for hyperammonemia. The trial, conducted in Australia, includes healthy volunteers and plans to dose Urea Cycle Disorder patients in early 2027, with interim results expected later that year.

Korro Bio, Inc. (KRRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update — KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical trial in second half of 2026 — Received Orphan

Biohaven has partnered with Ono Pharmaceutical in a $100m deal for its MoDE IgG degrader portfolio, including BHV-1300, BHV-1310, and BHV-1320. Ono gains exclusive rights in ASEAN, Taiwan, South Korea, and Japan, with an $80m upfront payment and a $20m milestone. Biohaven retains global rights and is eligible for 20% royalties. BHV-1300 is in Phase III trials for Graves' disease, showing up to 87% IgG reduction. According to Biohaven, Ono will help bring the technology to Asian markets.

Oppenheimer downgraded Pacira Biosciences from Outperform to Perform following its sale to Viatris. The stock has risen 44.4% in 5 days and 45.5% year-to-date.